Status:
UNKNOWN
Double Filtration Plasmapheresis Combined With Chemotherapy
Lead Sponsor:
Fuling Zhou
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment of abnormalities of M protein or renal function due to the multiple myeloma.
Eligibility Criteria
Inclusion
- Multiple myeloma patients who are diagnosed by bone marrow morphology and immunology
- Patients with stable condition after conventional treatment
- Patients with renal insufficiency or abnormal M protein
- Patients over 18 years of age
- Liver function: blood bilirubin ≤ 35μmol/L, enzymes aspartate transaminase (AST)/aka alanine aminotransferase (ALT) is less than 2 times the upper limit of normal
- Normal heart function
- Physical condition score 0-2 level (ECOG score)
- Obtain an informed consent form signed by the patient or family member
Exclusion
- Allergies or obvious contraindications to any of the drugs involved in the plan
- Severe heart disease, including myocardial infarction and cardiac insufficiency.
- Suffering from other organ malignancies
- Active tuberculosis patients and HIV-positive patients
- At the same time suffering from other blood system diseases
- Pregnant or lactating women
- Able to understand or follow the research plan
- Past history of intolerance or allergy to similar drugs
- Patients under 18 years of age
- Participating in other clinical researchers at the same time
- There are any other circumstances that hinder the progress of the research
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04836871
Start Date
May 15 2021
End Date
October 31 2024
Last Update
July 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071